Clinical trialPhase 3Withdrawn
An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
An Open-Label Extension Study to Evaluate the Safety and Efficacy of Oral Methylnaltrexone Bromide Tablets in Subjects With Advanced Pancreatic Cancer
- Outcome
- Stopped earlyDue to pandemic challenges and consideration of a different study design in the future. (Other)
- Phase
- Phase 3
- Status
- Withdrawn
- Study type
- Interventional
- Planned start
- 3 February 2020
- Planned end
- 3 February 2024
- Enrollment
- 0 participants
- Sites
- 0
- Primary outcomes
- Overall Survival
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 7 May 2021
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This open-label extension study will evaluate the long-term safety and efficacy of oral MNTX in participants with advanced pancreatic cancer (adenocarcinoma) who were previously enrolled in Study SAL-REL-2042 (NCT04083651).